Updates on HER2-Directed ADCs Across Solid Tumors - Episode 2

ADCs Targeting HER2+ Breast Cancer

, , , ,

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

EP. 1: Assessing HER2 Status Across Tumor Types
Now Viewing
EP. 2: ADCs Targeting HER2+ Breast Cancer
EP. 3: ADCs Targeting HER2+ Gynecologic Cancers
EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
EP. 5: ADCs Targeting GI Cancers
EP. 6: ADCs Targeting HER2+ Lung Cancer
EP. 7: Impact of ADCs on Brain Metastases
EP. 8: ADCs Targeting HER2+ GU Cancers
EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
EP. 11: Managing ILD and Pneumonitis Risk From ADCs
EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
EP. 13: Managing Hematologic AEs Associated with ADC Treatments
EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates
EP. 15: ADC Sequencing
EP. 16: Emerging ADCs in Development
EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
EP. 18: The Future for HER2-Directed ADCs
EP. 19: Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

  • Please briefly review the pivotal data that led to the approval of trastuzumab emtasin (T-DM1) for HER2+ Breast Cancer
    • EMILIA and Dieras_Lancet Oncol_2017 Final OS Analysis
    • TH3RESA and Krop_Lancet Oncol 2017 Final OS: HER2+ aBC
    • KATHERINE and Loibl SABSC Final IDFS and OS Analysis: adjuvant treatment in HER2+ early BC
  • Please briefly review the data that led to FDA approval for trastuzumab deruxtecan (T-DXd) for HER2+ Breast Cancer, plus other recent updates